Disease Landscape and Forecast Insights

Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds…

Dyslipidemia is an important modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), a leading causes of death globally. Statins continue to dominate treatment for dyslipidemia,…

Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD), which is primarily managed by statin therapy. With positive CV outcomes data for certain nonstatin therapies including…

Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds…

MARKET OUTLOOK Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid…

Hypertriglyceridemia refers to abnormalities in the concentration of triglycerides in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease and, with very high levels…

Hypertriglyceridemia is characterized by elevated triglyceride (TG) levels. In addition to lifestyle changes, current treatment focuses on improving patients’ TG levels with the aim to reduce the…

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9…

Dyslipidemia is an important modifiable risk factor for cardiovascular disease, which is one of the leading causes of death globally. Statins continue to dominate treatment of dyslipidemia, driven…

MARKET OUTLOOK Dyslipidemia is an important modifiable risk factor for CV disease and is primarily managed with statin therapy. Based on the positive CVOT data for certain nonstatin therapies,…

Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (CV) disease…

Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The most common lipid abnormalities include…